|
|
| (62 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Interferon beta-1a]] |
| |genericName=Interferon Beta-1A
| |
| |aOrAn=an
| |
| |drugClass=immunologic adjuvant
| |
| |indicationType=treatment
| |
| |indication=[[multiple sclerosis]]
| |
| |adverseReactions=flu-like symptoms including chills, [[fever]], [[myalgia]], and [[asthenia]]
| |
| |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| |
| |fdaLIADAdult='''Multiple Sclerosis, Relapsing forms'''
| |
| AVONEX (interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
| |
| |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Interferon Beta-1A in adult patients.
| |
| |offLabelAdultNoGuideSupport=====Multiple sclerosis, Clinically Isolated Syndrome====
| |
| Efficacy has been demonstrated in patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
| |
| |fdaLIADPed=Safety and effectiveness in pediatric patients have not been established.
| |
| |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Interferon Beta-1A in pediatric patients.
| |
| |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Interferon Beta-1A in pediatric patients.
| |
| |alcohol=Alcohol-Interferon Beta-1A interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| }}
| |